User programme promises to cut review times by a quarter
This article was originally published in Clinica
Executive Summary
The FDA is promising an average 25% improvement in review times with the additional funds collected under the user fee programme. The 25% improvement is an average for all types of premarket submissions, including PMAs, PMA supplements, 510(k)s, and biological licence applications (BLA) used for review of new blood centre devices.